Breaking News

Cellares Raises $257M to Industrialize Global Cell Therapy Manufacturing

Funding aims to enable global commercial launch and supply of cell therapies.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Cellares

Cellares, an Integrated Development and Manufacturing Organization (IDMO), announced a $257 million Series D financing co‑led by investment funds managed by BlackRock and Eclipse, bringing the company’s total capital raised to $612 million.  The Series D adds a new group of global investors, including accounts advised by T. Rowe Price Investment Management, Inc., Baillie Gifford, Duquesne Family Office, Intuitive Ventures, EDBI, and Gates Frontier, alongside continued participation from exist...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters